Market Flux Event

FDA Rejects Summit Therapeutics Ivonescimab for Lung Cancer, Demands Overall Survival Data

Read this in the Market Flux app

The U.S. Food and Drug Administration issued a Complete Response Letter on November 15, 2026, refusing to approve Summit Therapeutics' Biologics License Application for ivonescimab, a novel PD-1 x VEGF bispecific antibody, in combination with platinum-containing chemotherapy for locally advanced or metastatic non-small cell lung cancer in patients who had received prior EGFR tyrosine kinase inhibitor therapy. The BLA was based on the HARMONi study. The FDA concluded that substantial evidence of effectiveness had not been established because the drug failed to show a statistically significant overall survival benefit, and that progression-free survival gains alone were insufficient to support a positive benefit-risk profile.

Shares of Summit Therapeutics fell roughly 14 to 20 percent in premarket trading on November 16 and hit a 52-week low during the session. The FDA's position is notable given that, by Summit's own account, there are currently no FDA-approved regimens that have demonstrated a statistically significant overall survival benefit in this same patient setting. The drug, backed by AstraZeneca, had been among the most closely watched oncology programs in biotech. The company will need to generate overall survival data before it can refile.

Elsewhere in oncology, CG Oncology reported strongly positive Phase 3 results from its PIVOT-006 registrational trial of cretostimogene grenadenorepvec in non-muscle invasive bladder cancer, showing a 68 percent reduction in recurrence risk versus control, with a hazard ratio of 0.32 (p less than 0.0001) and no Grade 3 or higher treatment-related adverse events. CG Oncology shares climbed on the news, and topline results are set for a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on December 2, 2026. Lexeo Therapeutics shares surged roughly 25 percent premarket after interim Phase 1/2 data showed its LX2020 gene therapy reduced non-sustained ventricular tachycardia by 80 percent and premature ventricular contractions by 44 percent in patients with PKP2-associated arrhythmogenic cardiomyopathy.

© AI-generated summary is provided by Market Flux

Sources

  1. BioStocks$SMMT ↓ 20% PM FDA issued CRL for Ivonescimab BLA
  2. NasdaqSummit Therapeutics Inc. Receives FDA Complete Response Letter on November 15, 2026
  3. BenzingaSummit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
  4. Briefingcom$LXEO: Lexeo Therapeutics reported interim Phase I/II data showing high-dose LX2020 reduced non-sustained ventricular tachycardia by 80% and premature ventricular contractions by 44%.
  5. GurufocusBioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
  6. Business WireESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
  7. Market WatchThe FDA declined to approve one of biotech's most closely watched cancer drugs
  8. MarketWatchThe FDA declined to approve one of biotech’s most closely watched cancer drugs
Show 8 more
  1. TheTradeXchange$CGON - PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
  2. InvestingNuvation Bio presents long-term data on brain cancer drug
  3. OpenOutcrier$BLRX (+6.9% pre) BioLineRx initiates fourth cohort in GLIX1 brain tumor trial
  4. BarronsSummit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
  5. BarronsonlineSummit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
  6. BPharmCatalyst$HELP announced positive Phase 3 APPROACH data for HLP003 (deuterated psilocin) as an adjunct in major depressive disorder (n=222). The trial met its primary endpoint with a 7.6-point placebo-adjusted MADRS reduction at Week 6 (p<0.0001), sustained at 7.0 points through Week 12. Week 6 response and remission rates were 56.3% and 50.9% versus 28.2% and 18.2% for placebo, with onset by Day 2. Three treatment-related SAEs occurred; Phase 3 EMBRACE results are expected in Q4 2027. $ACRS $LXEO $CRDF $OCS $HELP $DRTS $AKAN $INAB $XRTX $ADXN See More Pre-market Movers at BioPharmCatalyst in the Articles Menu
  7. Marketwirenews$CGON - PIVOT006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in RecurrenceFree Survival RFS for IntermediateRisk and HighGrade Ta NonMuscle Invasive Bladder Cancer NMIBC – Cretostimogene reduced the risk of recurrence by 68%, demonstrating a statistically significant and clinically meaningful benefit with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001) – Compelling safety and tolerability results, no Grade 3 or higher TRAEs and no tre... News & Disclaimer
  8. WallstengineWEGOVY CUT CHILDREN'S BMI BY 13.5% Novo Nordisk $NVO published full results from its STEP Young phase 3 trial in the New England Journal of Medicine, testing once-weekly semaglutide in children aged 6 to 11 with obesity. More than 85% had severe obesity at the start of the trial. At week 68: - BMI fell 13.5%, versus a 2.7% increase with placebo. - 74.7% achieved at least a 10% BMI reduction. - 38.4% were no longer classified as having obesity. But by week 104, the average BMI reduction had narrowed to 9.4%. The share achieving at least a 10% reduction fell to 63.5%, while 33.3% were no longer classified as obese. Interestingly, the advantage over placebo actually widened from 16.2 to 17.8 percentage points because children in the placebo group continued gaining BMI. Novo reported no new safety concerns involving growth or puberty, although longer-term developmental effects remain an important consideration. Semaglutide is not currently approved in the U.S. for children under 12. Source: Novo Nordisk, NEJM